This is a StreetInsider.com Premium Only Page

Salarius Pharmaceuticals, Inc. (SLRX) –

Apr 12, 2024 04:51 PM Form 4 Salarius Pharmaceuticals For: Apr 11 Filed by: Arthur David J.

Mar 26, 2024 04:06 PM Form DEFA14A Salarius Pharmaceuticals

Mar 26, 2024 04:04 PM Form DEF 14A Salarius Pharmaceuticals For: Dec 31

Mar 22, 2024 04:13 PM Form 10-K Salarius Pharmaceuticals For: Dec 31

Mar 22, 2024 04:05 PM Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 20, 2024 06:01 AM Form DFAN14A Salarius Pharmaceuticals Filed by: Lee Elvin Sanghwan

Mar 15, 2024 05:04 PM Form PRE 14A Salarius Pharmaceuticals For: Dec 31

Mar 6, 2024 04:02 PM Form 8-K Salarius Pharmaceuticals For: Mar 05

Feb 23, 2024 06:07 AM Salarius Pharmaceuticals (SLRX) Enters Separation Agreement with CEO

Feb 23, 2024 06:01 AM Form 8-K Salarius Pharmaceuticals For: Feb 20

Feb 22, 2024 04:37 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: Rosenblum Mark J

Feb 22, 2024 04:30 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: McVicar William K.

Feb 22, 2024 04:25 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: McCreedy Bruce J Jr.

Feb 22, 2024 04:22 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: Lieber Jonathan I

Feb 22, 2024 04:16 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: Lammers Paul

Feb 22, 2024 04:13 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: Burleson Tess

Feb 22, 2024 04:10 PM Form 4 Salarius Pharmaceuticals For: Feb 20 Filed by: HANISH ARNOLD C

Feb 22, 2024 08:00 AM Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts

Feb 22, 2024 08:00 AM Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Feb 14, 2024 03:55 PM Form SC 13G Salarius Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC

Jan 16, 2024 08:17 AM Salarius Pharmaceuticals, Inc. (SLRX) Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Jan 16, 2024 08:00 AM Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Jan 3, 2024 08:54 AM Salarius Pharmaceuticals (SLRX) Announces FDA Removal of Clinical Hold on Seclidemstat Trial

Jan 3, 2024 08:30 AM Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Nov 9, 2023 05:05 PM Form 10-Q Salarius Pharmaceuticals For: Sep 30

Nov 7, 2023 08:31 AM Salarius Pharmaceuticals, Inc. (SLRX) Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023 08:30 AM Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Oct 27, 2023 03:58 PM Form SC 13D Salarius Pharmaceuticals Filed by: Lee Elvin Sanghwan

Sep 6, 2023 05:10 PM Form 8-K Salarius Pharmaceuticals For: Sep 05

Aug 11, 2023 05:53 AM Salarius Pharmaceuticals, Inc. (SLRX) Reports Q2 Loss of $1.43

Aug 10, 2023 04:15 PM Form 8-K Salarius Pharmaceuticals For: Aug 10

Aug 10, 2023 04:14 PM Form 10-Q Salarius Pharmaceuticals For: Jun 30

Aug 10, 2023 04:05 PM Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 8, 2023 04:10 PM Salarius Pharmaceuticals (SLRX) Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

Aug 8, 2023 04:05 PM Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

Aug 8, 2023 04:03 PM Salarius Pharmaceuticals, Inc. (SLRX) Halted, News Pending

Jul 12, 2023 09:22 AM Form 8-K Salarius Pharmaceuticals For: Jul 11

Jul 11, 2023 08:33 AM Salarius Pharmaceuticals (SLRX) Granted FDA Clearance of SP-3164 Investigational NDA

Jul 11, 2023 08:30 AM Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jun 15, 2023 06:14 AM Form 8-K Salarius Pharmaceuticals For: Jun 14

Jun 12, 2023 08:01 AM Salarius Pharmaceuticals (SLRX) Presents SP-3164 Targeted Protein Degrader Preclinical Data

Jun 12, 2023 08:00 AM Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 8, 2023 06:02 AM Form EFFECT Salarius Pharmaceuticals

Jun 7, 2023 07:28 AM Form 424B3 Salarius Pharmaceuticals

Jun 1, 2023 05:02 PM Form S-3/A Salarius Pharmaceuticals

May 26, 2023 05:03 PM Form S-3 Salarius Pharmaceuticals

May 25, 2023 03:13 PM Form D Salarius Pharmaceuticals

May 16, 2023 04:34 PM Form 8-K Salarius Pharmaceuticals For: May 11

May 16, 2023 04:05 PM Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023 08:02 AM Salarius Pharmaceuticals (SLRX) Announces $6 Million Private Placement of Common Stock, Warrants